painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.
Company profile
Ticker
PRFX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PRFX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
17 Apr 24
424B3
Prospectus supplement
17 Apr 24
424B4
Prospectus supplement with pricing info
17 Apr 24
EFFECT
Notice of effectiveness
17 Apr 24
6-K
PainReform Announces Pricing of $4 Million Public Offering
16 Apr 24
F-1/A
Registration statement (foreign) (amended)
15 Apr 24
6-K
Current report (foreign)
9 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical
2 Apr 24
EFFECT
Notice of effectiveness
15 Mar 24
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
24 Apr 24
SC 13G/A
GELLER EHUD
15 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
XT Holdings Ltd.
23 Jan 24
SC 13G/A
GELLER EHUD
2 Mar 23
SC 13G/A
GELLER EHUD
11 Feb 22
SC 13G/A
XT Holdings Ltd.
25 Jan 22
SC 13G
GELLER EHUD
16 Feb 21
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 21
SC 13G/A
SABBY MANAGEMENT, LLC
7 Jan 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 37.94 mm |
Total shares | 4.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Geller Ehud | 3.29 mm | $0.00 |
XT | 1.42 mm | $1.88 mm |
Renaissance Technologies | 31.00 k | $17.00 k |
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 30.00 k | $16.47 mm |
Citadel Advisors | 19.98 k | $10.97 mm |
Geode Capital Management | 19.11 k | $8.25 mm |
UBS UBS Group AG - Registered Shares | 639.00 | $351.00 k |
Proequities | 0.00 | $0.00 |
News
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
10 Apr 24
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
10 Apr 24
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
9 Apr 24
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
2 Apr 24